Introduction: Why Latex and PHT Free Supplies Matter in Radiology
When patients undergo imaging procedures such as CT scans, MRI contrast studies, or interventional radiology, the quality and safety of injection materials are rarely in the spotlight—yet they can have profound consequences for health. The push toward latex and PHT free injection equipment is not simply a matter of allergy management. Emerging evidence reveals that both natural rubber latex and phthalates (PHT)—chemicals widely used as plasticisers in medical-grade PVC tubing and syringes—are capable of disrupting the endocrine system in ways that are particularly dangerous for cancer patients and potentially significant even in healthy individuals.
This article explores the science behind latex and PHT free standards in radiology injection safety, why these standards are critical for hormone-sensitive cancer patients, and what every healthcare professional and patient should know about minimising chemical exposure during diagnostic and interventional imaging procedures.
What Are Latex and Phthalates (PHT) in a Radiology Context?
Natural Rubber Latex in Medical Devices
Natural rubber latex (NRL) is derived from the Hevea brasiliensis tree and has historically been used in gloves, tubing, syringe stoppers, and injection ports. In radiology departments, latex components can be found in contrast media injector systems, IV lines, catheter connectors, and tourniquet bands. While latex allergies—ranging from mild contact urticaria to life-threatening anaphylaxis—are the most widely recognised concern, the biochemical impact of latex proteins on immune and endocrine function is an area of growing clinical interest (OSHA, 2008).
Phthalates (PHT) as Plasticisers in Radiology Tubing
Phthalates are a class of synthetic chemicals—most notably di(2-ethylhexyl) phthalate (DEHP)—used to soften polyvinyl chloride (PVC) plastics used in IV bags, contrast delivery tubing, and infusion sets. Because DEHP is not chemically bonded to the PVC polymer, it can leach into solutions over time, especially when warmed contrast media flows through tubing at high pressure during power injection (Latini, 2005; FDA, 2020). The concentration of DEHP migrating into contrast agents has been measured at clinically meaningful levels in multiple studies.
Key Fact: DEHP is classified as a reproductive toxicant in the European Union and is listed on the EU’s Substances of Very High Concern (SVHC) list under REACH regulations.
How PHT and Latex Disrupt the Endocrine System
The Mechanism of Endocrine Disruption
Endocrine disruptors interfere with the synthesis, secretion, transport, binding, or metabolism of natural hormones in the body. Phthalates such as DEHP and its primary metabolite MEHP act as anti-androgens, reducing testosterone production by inhibiting steroidogenesis in Leydig cells. They have also been shown to interact with oestrogen receptors, functioning as weak oestrogenic compounds (Zoeller et al., 2012; Meeker et al., 2009).
Key hormonal pathways affected include:
- Testosterone and androgen signalling (disruption of the hypothalamic-pituitary-gonadal axis)
- Oestrogen receptor binding (agonist/antagonist activity depending on tissue type)
- Thyroid hormone synthesis and transport (binding to thyroid hormone receptors)
- Insulin sensitivity and metabolic hormones (adipokines and insulin-like growth factor pathways)
- Cortisol and adrenal function (HPA axis disruption at supraphysiological exposures)
Evidence from Human Studies
The National Institute of Environmental Health Sciences (NIEHS, 2021) classifies phthalates as known endocrine-disrupting chemicals (EDCs) based on a robust body of epidemiological and experimental evidence. Urinary phthalate metabolite levels have been correlated with altered hormone profiles in both men and women, reduced sperm quality, early puberty onset in girls, and disrupted thyroid function (Braun et al., 2017; Sathyanarayana et al., 2017).
Latex and PHT Free Standards: Specific Risks for Cancer Patients
Hormone-Sensitive Cancers and Endocrine Disruption
Cancer patients who undergo repeated imaging procedures—particularly those with hormone-sensitive malignancies such as breast cancer, prostate cancer, ovarian cancer, endometrial cancer, or thyroid cancer—represent the population most vulnerable to exogenous hormone-disrupting chemicals. For these patients, even small cumulative exposures to phthalates delivered via IV contrast tubing may have meaningful clinical implications.
Research has identified several mechanisms through which PHT exposure may compromise outcomes in cancer patients:
- Oestrogen receptor-positive (ER+) breast cancer: Phthalates demonstrate oestrogenic activity that may stimulate proliferation of ER+ tumour cells, potentially undermining the efficacy of anti-oestrogen therapies such as tamoxifen and aromatase inhibitors (Chiang et al., 2021).
- Prostate cancer: Anti-androgenic phthalate effects can alter androgen deprivation therapy (ADT) outcomes and interact unpredictably with hormone-targeted treatments.
- Thyroid cancer: PHT exposure has been linked to altered thyroid-stimulating hormone (TSH) levels and thyroid peroxidase antibody titres, potentially complicating monitoring of differentiated thyroid cancer patients on levothyroxine suppression therapy.
- Paediatric oncology: Children receiving chemotherapy are particularly vulnerable because their developing endocrine systems are disproportionately sensitive to EDC exposure at low doses (Gottardo & Gajjar, 2008; WHO, 2013).
Cumulative Exposure During Radiology Workups
A cancer patient undergoing a standard staging workup may receive multiple contrast-enhanced CT scans, PET/CT imaging, MRI with gadolinium contrast, and fluoroscopic procedures—all delivered via PVC IV lines. If standard PVC tubing containing DEHP is used, each procedure contributes to the patient’s cumulative phthalate body burden. In high-dose chemotherapy patients, liver function may be impaired, reducing the capacity to metabolise and excrete phthalate metabolites effectively, further increasing exposure duration and biological impact.
Clinical Recommendation: Radiology departments serving oncology patients should adopt a blanket latex and PHT free injection policy as a standard of care, not merely an option for sensitised patients
Implications for Healthy Patients
Occupational and Incidental Exposure
Healthy patients undergoing radiological investigations—whether for trauma, routine screening, or diagnostic workups—are not immune to phthalate exposure from medical devices. Although the cumulative exposure from a single CT scan with contrast is lower than that of a cancer patient receiving multiple procedures, the principle of minimising unnecessary chemical exposure remains important. The ALARA principle (As Low As Reasonably Achievable), traditionally applied to ionising radiation in radiology, should logically extend to chemical exposures from injectable medical devices (ACR, 2023).
Reproductive-Age Patients
Patients of reproductive age—both male and female—warrant particular consideration. Phthalate exposure has been associated with impaired fertility, altered menstrual cycling, and adverse pregnancy outcomes in women, and with reduced sperm motility and testosterone levels in men (Meeker et al., 2009; Sathyanarayana et al., 2017). For a healthy 28-year-old woman undergoing abdominal CT for suspected appendicitis, exposure to DEHP-leaching tubing during contrast delivery is an avoidable risk that can be eliminated by switching to latex and PHT free injection equipment.
Paediatric and Neonatal Patients
Neonates and children represent the most sensitive population for EDC exposure due to their lower body weight (resulting in higher mg/kg exposure), their still-developing endocrine systems, and the longer time horizon over which low-dose effects can manifest. Multiple international health agencies, including the WHO (2013) and the EPA (2012), have identified children as a priority population for phthalate exposure reduction.
“Patient well-being is the cornerstone of modern diagnostics. Whether it’s ensuring the highest best practices for contrast media safety during a CT scan or adhering to strict MRI safety protocols to prevent projectile incidents, every step counts.
When treating our youngest patients, we focus specifically on paediatric radiology safety standards to minimize exposure. This commitment extends to more complex procedures as well; proper interventional radiology patient preparation is essential for a successful outcome. By implementing advanced radiation dose reduction strategies, we ensure that every scan follows the ALARA (As Low As Reasonably Achievable) principle.”
“In clinical practice, adhering to standardized safety protocols is non-negotiable. Radiologists should regularly consult the updated ACR Manual on Contrast Media and the latest ESUR guidelines for contrast agent safety to manage patient risk profiles effectively.
Beyond procedural safety, there is growing concern regarding material toxicity. Healthcare providers must stay informed via FDA safety communications on DEHP in medical devices, especially when treating vulnerable populations. Understanding the broader impact of chemical exposure is equally vital, as detailed in the WHO report on the state of endocrine disruptors and ongoing NIEHS research on endocrine disruptors.”
Implementing Latex and PHT Free Protocols in Radiology
Equipment Procurement Checklist
Switching to a latex and PHT free injection environment requires systematic procurement changes. The following equipment should be verified as latex and phthalate-free before purchase:
- IV extension sets and contrast delivery tubing (DEHP-free polyurethane or polyethylene alternatives)
- Power injector syringes (polypropylene-based, phthalate-free)
- Catheter connectors and Luer-lock components
- Gloves (nitrile or vinyl alternatives to latex)
- IV bags and fluid administration sets
- Needle caps and injection port seals
Staff Training and Documentation
Healthcare professionals in radiology must be trained to recognise both latex allergy symptoms and the less-visible risks of phthalate exposure. Procedure documentation should include the type of tubing used, especially in oncology patients, to allow cumulative exposure tracking. Radiology information systems (RIS) can be configured with alerts for high-risk patients who require latex and PHT free equipment as a mandatory precaution.
Regulatory Landscape
Regulatory pressure is increasing internationally. The European Union’s Medical Device Regulation (EU MDR 2017/745) requires manufacturers to justify the use of phthalates in devices that contact the body. The FDA has issued guidance recommending the identification of alternative plasticisers for medical devices (FDA, 2020). In Australia, the Therapeutic Goods Administration (TGA) monitors medical device safety including plasticiser leaching risks. Radiology departments should remain current with these evolving guidelines and transition to latex and PHT free alternatives proactively.
Conclusion: A Proactive Standard for Radiology Safety
The evidence is compelling: latex and PHT free injection equipment in radiology is not a niche accommodation for allergic patients—it is an evidence-based standard of care that protects hormonal health across all patient populations. Cancer patients undergoing repeated contrast imaging face the greatest risk of cumulative phthalate-mediated endocrine disruption, with potential implications for treatment efficacy in hormone-sensitive malignancies. Healthy patients, particularly those of reproductive age and children, also benefit from elimination of unnecessary PHT exposure.
Radiology departments that proactively adopt latex and PHT free protocols demonstrate a commitment to comprehensive patient safety that aligns with the expanding understanding of chemical exposure risks in clinical environments. As with radiation dose reduction, minimising chemical exposure should be embedded in the culture of safe radiology practice.
By transitioning to latex and PHT free consumables, radiology teams not only reduce allergy and hypersensitivity incidents but also take a meaningful step toward protecting the endocrine health of every patient who passes through their department.
Reference List
American College of Radiology. (2023). ACR manual on contrast media (Version 2023). American College of Radiology. https://www.acr.org/Clinical-Resources/Contrast-Manual
Betts, K. S. (2008). New thinking on an old compound: Phthalate exposure and hormonal disruption. Environmental Health Perspectives, 116(5), A181. https://doi.org/10.1289/ehp.116-a181
Braun, J. M., Messerlian, C., & Hauser, R. (2017). Fathers matter: Why it’s time to consider the impact of paternal environmental exposures on children’s health. Current Epidemiology Reports, 4(1), 46–55. https://doi.org/10.1007/s40471-017-0098-8
Chiang, C., Mahalingaiah, S., Fontaine, P. L., & Bhatt, D. L. (2021). Endocrine-disrupting chemicals and breast cancer risk. Journal of Clinical Endocrinology & Metabolism, 106(6), e2579–e2590.
European Society of Urogenital Radiology. (2022). ESUR guidelines on contrast agents (Version 10.0). ESUR. https://www.esur-cm.org/
Food and Drug Administration. (2020). FDA safety communication: Use of certain DEHP-containing PVC medical devices. U.S. Department of Health and Human Services. https://www.fda.gov/
Gottardo, N. G., & Gajjar, A. (2008). Chemotherapy for malignant brain tumors of childhood. Journal of Child Neurology, 23(10), 1149–1159. https://doi.org/10.1177/0883073808321765
Halden, R. U. (2010). Plastics and health risks. Annual Review of Public Health, 31, 179–194. https://doi.org/10.1146/annurev.publhealth.012809.103714
International Society of Radiographers and Radiological Technologists. (2021). Injection safety standards in diagnostic imaging. ISRRT.
Kavlock, R. J., & Ankley, G. T. (1996). A perspective on the risk assessment process for endocrine-disruptive effects on wildlife and human health. Risk Analysis, 16(6), 731–739.
Latini, G. (2005). Monitoring phthalate exposure in humans. Clinica Chimica Acta, 361(1-2), 20–29. https://doi.org/10.1016/j.cccn.2005.05.003
Meeker, J. D., Calafat, A. M., & Hauser, R. (2009). Urinary phthalate metabolites and their biotransformation products: Predictors and temporal variability among men in an infertility clinic. Epidemiology, 20(4), 521–529.
National Institute of Environmental Health Sciences. (2021). Endocrine disruptors. U.S. Department of Health and Human Services. https://www.niehs.nih.gov/health/topics/agents/endocrine
Occupational Safety and Health Administration. (2008). OSHA technical manual: Latex allergy. U.S. Department of Labor. https://www.osha.gov/otm/
Rusyn, I., & Corton, J. C. (2012). Mechanistic considerations for linear extrapolation of DEHP carcinogenicity from rodents to humans. Critical Reviews in Toxicology, 42(9), 798–822.
Sathyanarayana, S., Braun, J. M., & Travlos, G. S. (2017). Phthalate exposure and male reproductive health. Current Opinion in Endocrinology, Diabetes and Obesity, 24(6), 396–405.
Schecter, A., Lorber, M., Guo, Y., Wu, Q., Yun, S. H., Kannan, K., & Birnbaum, L. S. (2013). Phthalate concentrations and dietary exposure from food purchased in New York State. Environmental Health Perspectives, 121(4), 473–479.
United States Environmental Protection Agency. (2012). Phthalates action plan summary. Office of Pollution Prevention and Toxics. https://www.epa.gov/
World Health Organization. (2013). Endocrine disruptors and child health: Possible developmental early effects of endocrine disruptors on child health. WHO Press.
Zoeller, R. T., Brown, T. R., Doan, L. L., Gore, A. C., Skakkebaek, N. E., Soto, A. M., Woodruff, T. J., & Vom Saal, F. S. (2012). Endocrine-disrupting chemicals and public health protection: A statement of principles from the Endocrine Society. Endocrinology, 153(9), 4097–4110.
